KARDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Kardigan, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$12.94−0.09 (-0.69%)
Close on Oct 19, 2026
- Market cap
- $326.04M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
61.2%
57M of 94M shares
Institutional holders
69
69 new, 0 sold out
Net institutional buying
57M
In Q2 2026
Insider trades, 12 months
3 buys · 0 sales
Net bought $90.00M
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| FMR LLC | 9,221,774 | 10.30% | 13G (passive) amendment | Jul 31, 2026 |
| Joseph Edelman | 8,254,144 | 8.90% | 13D (active) | Jun 18, 2026 |
| Perceptive Advisors LLC | 8,254,144 | 8.80% | 13D (active) amendment | Sep 29, 2026 |
| Edelberg Jay | 4,878,105 | 5.20% | 13G (passive) | Jun 30, 2026 |
| Kevin Anthony Kelly | 16,917,034 | 18.20% | 13G (passive) | Jun 22, 2026 |
| Paul Berns | 15,095,518 | 16.20% | 13D (active) | Jun 22, 2026 |
| Gianakakos Anastasios | 10,470,294 | 11.10% | 13G (passive) | Jun 30, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of KARD | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Schf (Gpe), LLC | 16,917,034 | 18.09% | $403.47M | New | 16.26% |
| FMR LLC | 8,909,066 | 9.53% | $212.48M | New | 0.01% |
| Perceptive Advisors LLC | 8,200,662 | 8.77% | $195.59M | New | 2.94% |
| T. Rowe Price Investment Management, Inc. | 4,207,130 | 4.50% | $100.34K | New | 0.07% |
| Capital Research Global Investors | 3,598,942 | 3.85% | $85.83M | New | 0.01% |
| JPMorgan Chase & Co | 1,790,734 | 1.92% | $46.38M | New | 0.00% |
| Alliancebernstein L.P. | 1,534,837 | 1.64% | $36.61M | New | 0.01% |
| Liberty Mutual Group Asset Management Inc. | 1,196,411 | 1.28% | $28.53M | New | 2.49% |
| Jennison Associates LLC | 903,575 | 0.97% | $21.55M | New | 0.01% |
| Paradigm Biocapital Advisors LP | 900,000 | 0.96% | $21.47M | New | 0.40% |
| Jupiter Topco LLC | 749,703 | 0.80% | $17.72M | New | 0.01% |
| Price T Rowe Associates Inc /Md/ | 658,787 | 0.70% | $15.71K | New | 0.00% |
| Massachusetts Financial Services Co /Ma/ | 650,000 | 0.70% | $15.50M | New | 0.00% |
| Goldman Sachs Group Inc | 644,969 | 0.69% | $15.38M | New | 0.00% |
| Deep Track Capital, LP | 600,000 | 0.64% | $14.31M | New | 0.21% |
| Woodline Partners LP | 413,980 | 0.44% | $9.87M | New | 0.03% |
| Franklin Resources Inc | 400,021 | 0.43% | $9.54M | New | 0.00% |
| Suvretta Capital Management, LLC | 400,000 | 0.43% | $9.54M | New | 0.17% |
| Bank of New York Mellon Corp | 377,758 | 0.40% | $9.01M | New | 0.00% |
| Catalio Capital Management, LP | 312,500 | 0.33% | $7.45M | New | 1.40% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 69 | 57M | 61.2% | 69 / 0 | 0 / 0 | 57M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of KARD | Value | % of fund | As of |
|---|---|---|---|---|---|
| SMALLCAP World Fund Inc | 3,503,842 | 3.75% | $83.57M | 0.09% | Jun 30, 2026 |
| Fidelity Contrafund | 1,090,645 | 1.17% | $26.01M | 0.01% | Jun 30, 2026 |
| JPMorgan Small Cap Growth Fund | 823,598 | 0.88% | $19.64M | 0.75% | Jun 30, 2026 |
| AB Small Cap Growth Portfolio | 741,883 | 0.79% | $17.69M | 0.56% | Jun 30, 2026 |
| T. Rowe Price Small-Cap Stock Fund, Inc. | 737,233 | 0.79% | $17.58M | 0.19% | Jun 30, 2026 |
| T. Rowe Price Small-Cap Value Fund, Inc. | 633,307 | 0.68% | $15.10M | 0.14% | Jun 30, 2026 |
| Eventide Healthcare & Life Sciences Fund | 596,411 | 0.64% | $14.22M | 0.80% | Jun 30, 2026 |
| T. Rowe Price New Horizons Fund, Inc. | 445,253 | 0.48% | $10.62M | 0.07% | Jun 30, 2026 |
| T. Rowe Price Institutional Small-Cap Stock Fund | 398,570 | 0.43% | $9.51M | 0.19% | Jun 30, 2026 |
| Fidelity Blue Chip Growth Fund | 352,100 | 0.38% | $7.33M | 0.01% | Jul 31, 2026 |
| Eventide Healthcare & Life Sciences Fund | 300,000 | 0.32% | $7.16M | 0.40% | Jun 30, 2026 |
| JPMorgan Small Cap Blend Fund | 265,242 | 0.28% | $6.33M | 0.37% | Jun 30, 2026 |
| Fidelity Contrafund K6 | 227,493 | 0.24% | $5.43M | 0.01% | Jun 30, 2026 |
| SmallCap Growth Fund I | 225,647 | 0.24% | $4.70M | 0.19% | Jul 31, 2026 |
| BNY Mellon Small/Mid Cap Growth Fund | 182,297 | 0.19% | $4.35M | 0.50% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Anastasios Gianakakos | President & CEO, Director | 9,806,633 | 10.49% | Jun 22, 2026 |
| Jay Edelberg | Chief Medical Officer | 4,595,383 | 4.91% | Jun 22, 2026 |
| John B. Moriarty | Chief Legal Officer | 47,784 | 0.05% | Jun 22, 2026 |
| Brianne Jahn | Chief Financial Officer | 79,640 | 0.09% | Jun 22, 2026 |
| Andy Pasternak | Chief Strategy Officer | 79,640 | 0.09% | Jun 22, 2026 |
| Capital Solutions Holdings LP Perceptive | Director | – | – | Jul 13, 2026 |
| Life Sciences Master Fund Ltd Perceptive | Director | – | – | Jul 13, 2026 |
| Advisors Llc Perceptive | Director | – | – | Jul 13, 2026 |
| Joseph Edelman | Director | 20,706 | 0.02% | Jul 13, 2026 |
| Robert Nelsen | Director, 10% owner | 15,042,035 | 16.09% | Jun 24, 2026 |
| Paul L. Berns | Director, 10% owner | 15,062,741 | 16.11% | Jun 24, 2026 |
| ARCH Venture Partners XIII, LLC | Director, 10% owner | – | – | Jun 24, 2026 |
| ARCH Venture Fund XIII, L.P. | Director, 10% owner | – | – | Jun 24, 2026 |
| ARCH Venture Partners XIII, L.P. | Director, 10% owner | – | – | Jun 24, 2026 |
| Steven Gillis | Director, 10% owner | – | – | Jun 24, 2026 |
| Keith Crandell | Director, 10% owner | – | – | Jun 24, 2026 |
| Kristina Burow | Director, 10% owner | – | – | Jun 24, 2026 |
| Timothy P. Walbert | Director | 20,706 | 0.02% | Jun 22, 2026 |
| Kimberly J. Popovits | Director | 20,706 | 0.02% | Jun 22, 2026 |
| David P. Meeker | Director | 20,706 | 0.02% | Jun 22, 2026 |
| Douglas E. Giordano | Director | 20,706 | 0.02% | Jun 22, 2026 |
| Hrtg Pv, L.P. | 10% owner | 16,917,034 | 18.09% | Jun 24, 2026 |
| Kevin Anthony Kelly | 10% owner | – | – | Jun 24, 2026 |
| Hrtg Gpe, Llc | 10% owner | – | – | Jun 24, 2026 |
| Keith Bryon Johnson | 10% owner | 13,792,034 | 14.75% | Jun 24, 2026 |
| Schf Cif 2024, L.P. | 10% owner | – | – | Jun 24, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Robert Nelsen Director, 10% owner | Jun 22, 2026 | Buy | +1,250,000 | $16.00 | $20.00M | 15,042,035 |
| Paul L. Berns Director, 10% owner | Jun 22, 2026 | Buy | +1,250,000 | $16.00 | $20.00M | 15,042,035 |
| Hrtg Pv, L.P. 10% owner | Jun 22, 2026 | Buy | +3,125,000 | $16.00 | $50.00M | 14,866,868 |
| Joseph Edelman Director | Jun 17, 2026 | Award | +20,706 | – | – | 20,706 |
| Douglas E. Giordano Director | Jun 17, 2026 | Award | +20,706 | – | – | 20,706 |
| Andy Pasternak Chief Strategy Officer | Jun 17, 2026 | Award | +79,640 | – | – | 79,640 |
| Keith Bryon Johnson 10% owner | Jun 17, 2026 | Conversion | +2,348,373 | – | – | 11,741,868 |
| Keith Bryon Johnson 10% owner | Jun 17, 2026 | Conversion | +3,242,993 | – | – | 9,393,495 |
| Keith Bryon Johnson 10% owner | Jun 17, 2026 | Conversion | +6,150,502 | – | – | 6,150,502 |
| Keith Bryon Johnson 10% owner | Jun 17, 2026 | Conversion | +2,050,166 | – | – | 2,050,166 |
| Brianne Jahn Chief Financial Officer | Jun 17, 2026 | Award | +79,640 | – | – | 79,640 |
| Anastasios Gianakakos President & CEO, Director | Jun 17, 2026 | Conversion | +41,001 | – | – | 2,422,520 |
| Anastasios Gianakakos President & CEO, Director | Jun 17, 2026 | Conversion | +28,702 | – | – | 5,665,090 |
| Anastasios Gianakakos President & CEO, Director | Jun 17, 2026 | Conversion | +498,692 | – | – | 498,692 |
| John B. Moriarty Chief Legal Officer | Jun 17, 2026 | Award | +47,784 | – | – | 47,784 |
| Jay Edelberg Chief Medical Officer | Jun 17, 2026 | Conversion | +97,587 | – | – | 135,543 |
| Jay Edelberg Chief Medical Officer | Jun 17, 2026 | Award | +47,784 | – | – | 183,327 |
| Kimberly J. Popovits Director | Jun 17, 2026 | Award | +20,706 | – | – | 20,706 |
| Paul L. Berns Director, 10% owner | Jun 17, 2026 | Award | +20,706 | – | – | 20,706 |
| Paul L. Berns Director, 10% owner | Jun 17, 2026 | Conversion | +13,792,035 | – | – | 13,792,035 |
| Robert Nelsen 10% owner | Jun 17, 2026 | Conversion | +13,792,035 | – | – | 13,792,035 |
| Timothy P. Walbert Director | Jun 17, 2026 | Award | +20,706 | – | – | 20,706 |
| David P. Meeker Director | Jun 17, 2026 | Award | +20,706 | – | – | 20,706 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.